Cargando…

Great efficacy of afatinib on a patient with lung adenocarcinoma harboring uncommon EGFR delE709_T710insD mutations: a case report

EGFR)-targeted drugs have been the first-line treatment for patients with EGFR-mutant non-small cell lung cancer (NSCLC), especially exon 19 deletions and L858R mutation in exon 21. However, there is insufficient evidence for other less common types of EGFR mutations, such as delE709_T710insD (del 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	An, Ning, Wang, Haoyi, Zhu, Hui, Yan, Weiwei, Jing, Wang, Kong, Li, Zhang, Yan, Yu, Jinming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752199/ https://www.ncbi.nlm.nih.gov/pubmed/31686847 http://dx.doi.org/10.2147/OTT.S221638

Ejemplares similares

Response to dacomitinib in advanced non-small-cell lung cancer harboring the rare delE709_T710insD mutation: A case report
por: Xu, Fei, et al.
Publicado: (2022)

Afatinib for the treatment of advanced non-small-cell lung cancer harboring an epidermal growth factor receptor exon 18 E709_T710delinsD mutation: a case report
por: Van Acker, Lander, et al.
Publicado: (2021)

A Lung Adenocarcinoma Patient With a Rare EGFR E709_T710delinsD Mutation Showed a Good Response to Afatinib Treatment: A Case Report and Literature Review
por: Wei, Yu, et al.
Publicado: (2021)

Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations
por: Li, Teng, et al.
Publicado: (2021)

Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review
por: Jiang, Yingying, et al.
Publicado: (2023)

Sinus Bradycardia in Carriers of the SCN5A-1795insD Mutation: Unraveling the Mechanism through Computer Simulations
por: Wilders, Ronald
Publicado: (2018)

SCN5A-1795insD founder variant: a unique Dutch experience spanning 7 decades
por: Proost, Virginnio M., et al.
Publicado: (2023)

Non‐small cell lung cancer with EGFR (L858R and E709X) and CNNB1 mutations responded to afatinib
por: Kunishige, Michihiro, et al.
Publicado: (2022)

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report
por: Yang, James Chih-Hsin, et al.
Publicado: (2022)

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
por: Lin, Ling, et al.
Publicado: (2020)

Functional modulation of atrio-ventricular conduction by enhanced late sodium current and calcium-dependent mechanisms in Scn5a(1798insD/+) mice
por: Rivaud, Mathilde R, et al.
Publicado: (2020)

Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation
por: Dong, Wei, et al.
Publicado: (2022)

Great Efficacy of Afatinib in a Patient with Lung Adenocarcinoma Harboring EGFR L833V/H835L Mutations: A Case Report
por: Long, Xiang, et al.
Publicado: (2020)

A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an EGFR-KDD and Response to Afatinib
por: Chen, Dong, et al.
Publicado: (2020)

Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis
por: Wang, Chunsheng, et al.
Publicado: (2023)

Lung Adenocarcinoma Patient Harboring EGFR-KDD Achieve Durable Response to Afatinib: A Case Report and Literature Review
por: Zhao, Lingling, et al.
Publicado: (2021)

Successful treatment of a lung adenocarcinoma patient with a novel EGFR exon 20-ins mutation with afatinib: A case report
por: Cai, Yangyang, et al.
Publicado: (2019)

Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation
por: Zöchbauer-Müller, Sabine, et al.
Publicado: (2021)

Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report
por: Fang, Yueh‐Fu, et al.
Publicado: (2021)

DELE1 tracks perturbed protein import and processing in human mitochondria
por: Fessler, Evelyn, et al.
Publicado: (2022)

Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations
por: Liang, Wenhua, et al.
Publicado: (2014)

Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study
por: Thongprasert, Sumitra, et al.
Publicado: (2019)

Mitochondrial stress is relayed to the cytosol by an OMA1-DELE1-HRI pathway
por: Guo, Xiaoyan, et al.
Publicado: (2020)

Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo
por: Kudo, Kenichiro, et al.
Publicado: (2017)

Afatinib 30 mg in the treatment of common and uncommon EGFR-mutated advanced lung adenocarcinomas: a retrospective, single-center, longitudinal study
por: Qian, Jie, et al.
Publicado: (2022)

Heterogeneity response to afatinib in gastric cancer patient with uncommon epidermal growth factor receptor (EGFR) mutations: a case report
por: Liu, Qin, et al.
Publicado: (2021)

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study
por: Pu, Xingxiang, et al.
Publicado: (2023)

Ubuntu 7.10 Linux: Unleashed
por: Hudson, Andrew, et al.
Publicado: (2008)

Therapeutic strategies for afatinib‐resistant lung cancer harboring HER2 alterations
por: Torigoe, Hidejiro, et al.
Publicado: (2018)

Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer harboring EGFR mutations
por: Tanaka, Kentaro, et al.
Publicado: (2017)

A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations
por: Tanaka, Hisashi, et al.
Publicado: (2018)

Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations
por: Masuda, Tomomi, et al.
Publicado: (2020)

Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations
por: Ko, Ryo, et al.
Publicado: (2021)

Successful Treatment of Afatinib-Refractory Non-Small Cell Lung Cancer with Uncommon Complex EGFR Mutations Using Pembrolizumab: A Case Report
por: Taniguchi, Yuri, et al.
Publicado: (2019)

Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients with Non-Small Cell Lung Cancer Carrying Uncommon EGFR Mutations: A Comparative Cohort Study in China (AFANDA Study)
por: Li, Hong-Shuai, et al.
Publicado: (2022)

EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
por: Le, Xiuning, et al.
Publicado: (2023)

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations
por: Park, Keunchil, et al.
Publicado: (2021)

Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation
por: Chen, Yen-Ju, et al.
Publicado: (2019)

Is there a role for sequential afatinib and osimertinib in patients with EGFR mutation?
por: Iwamoto, Natsuhiko, et al.
Publicado: (2022)

Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations
por: Shi, Chen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c2b64v7kk0ccfp4eu5f76o265d